-
1.发明授权公开(公告)号：US08008454B2
公开(公告)日：2011-08-30
申请号：US10433508
申请日：2001-12-10
申请人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
发明人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
CPC分类号： C07K14/505 , C07K14/59 , C07K2319/00
摘要： The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
摘要翻译： 本发明涉及融合蛋白，其中人促红细胞生成素（EPO）的羧基末端与羧基末端肽片段“ 人绒毛膜促性腺激素（HCG）的亚单位，编码融合蛋白的DNA，以及融合蛋白的制备方法。 融合蛋白具有增强的红细胞生成素的体内活性。
-
2.发明申请公开(公告)号：US20090221037A1
公开(公告)日：2009-09-03
申请号：US10433508
申请日：2001-12-10
申请人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
发明人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
IPC分类号： C12P21/06 , C07K14/505 , C07H21/04
CPC分类号： C07K14/505 , C07K14/59 , C07K2319/00
摘要： The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
摘要翻译： 本发明涉及将人促红细胞生成素（EPO）的羧基末端与人绒毛膜促性腺激素（HCG）的β亚基的羧基末端肽片段与编码融合蛋白质的DNA融合的融合蛋白质， 融合蛋白的制备。 融合蛋白具有增强的红细胞生成素的体内活性。
-
公开(公告)号：US07098318B2
公开(公告)日：2006-08-29
申请号：US10230454
申请日：2002-08-29
申请人： Dong-Eok Lee , Myung-Suk Oh , Bo-Sup Chung , Ji-Sook Park , Ki-Wan Kim
发明人： Dong-Eok Lee , Myung-Suk Oh , Bo-Sup Chung , Ji-Sook Park , Ki-Wan Kim
CPC分类号： C07K14/524 , A61K38/00 , C07K14/505 , C07K2319/00
摘要： The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
-
-
搜索结果
3 条记录 (耗时 0.026 秒)
